Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities
Net income (loss)	$ 6,844,798	$ (3,953,813)
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Depreciation and amortization	4,453,057	4,295,840
Change in fair value of warrant liability	(1,872,364)	1,912,487
Non-cash lease expense	5,963,123	5,272,409
Stock-based compensation	4,554,024	10,037,396
Change in inventory and receivable reserves	(67,548)	291,619
Loss on sale of equipment		1,129
Loss from equity interests in unconsolidated affiliate	3,664,058	1,509,704
Loss on Drawbridge Transaction	165,998
Write-off of acquired Drawbridge in-process research and development	1,563,015
Change in operating assets and liabilities
Accounts receivable	(2,886,874)	2,607,011
Related party Receivable	(231,191)	(84,340)
Related party payables	825,695	372,831
Inventories	(12,879,268)	(709,519)
Prepaid expenses and other assets	(2,417,918)	(107,336)
Accounts payable and accrued liabilities	6,199,815	1,061,060
Operating lease liabilities	(4,794,134)	(5,399,423)
Net cash provided by operating activities	9,084,286	17,107,055
Cash Flows from Investing Activities
Purchase of property and equipment	(4,311,015)	(1,193,642)
Acquisition of Drawbridge Health assets, net of cash acquired	(1,412,279)
Purchase of investment in equity-method investments	(704,637)	(615,015)
Purchase of investment in unconsolidated subsidiaries		(750,000)
Purchase of license agreements	(750,457)	(1,128,621)
Net cash used in investing activities	(7,178,388)	(3,687,278)
Cash Flows from Financing Activities
Proceeds from issuance of common stock in IPO	70,000,000
Payoff of line of credit	(20,000,000)	(11,204,731)
Repayment of loan from related party		(3,000,000)
Proceeds from revolving line of credit		20,000,000
Payments on long-term debt and finance leases	(1,242,948)	(378,191)
Dividends paid on convertible preferred stock		(3,266,918)
Common stock issuance costs	(9,999,748)
Proceeds from exercise of common stock warrants		22,221,173
Repurchase of common stock		(23,119,913)
Payments for loans to management		(710,000)
Proceeds from repayment of loans to management		710,000
Proceeds from exercise of stock options	75,619	127,249
Net cash provided by financing activities	38,832,923	1,378,669
Net Increase in Cash and restricted cash	40,738,821	14,798,446
Cash and restricted cash, beginning of period	15,262,094	463,648
Cash and restricted cash, end of period	56,000,915	15,262,094
Supplemental Disclosure of Cash Flows Information
Cash paid during the year for interest	383,569	1,136,731
Income taxes, net of refunds	192,618	40,007
Noncash Investing and Financing Activities
Equipment acquired through finance lease obligations	540,433	694,108
Equipment acquired through debt obligations	1,274,601	893,600
Right-of-use assets obtained in exchange for lease liabilities	2,913,002	4,259,688
Conversion of Series E convertible preferred stock to common stock	133,484,531
Conversion of Class B common stock to common stock	$ 61,793